

## Thyroid gland

MUNI Med

- Glandula thyroidea (15 20 g, frontal side of trachea under thyroid cartilage
- Two lobes connected by thyroidal isthmus, lobus pyramidalis
- Strong vascularization
- Round follicles (acini) with one layer of follicular cells (T3/T4)
- Cavity filled with colloid
- Capillaries with fenestrations
- Parafollicular (C-) cells (calcitonin)
- From day 29 of gravidity (Tg), T4 11th week




**Figure 49-1** Structure of the thyroid gland. The thyroid gland is located anterior to the cricoid cartilage in the anterior neck. The gland comprises numerous follicles, which are filled with colloid and lined by follicular cells. These follicular cells are responsible for the trapping of iodine, which they secrete along with thyroglobulin—the major protein of the thyroid colloid—into the lumen of the follicle.



MED

## Iodine and hormone secretion – general view


- NIS (Na<sup>+</sup>/I<sup>-</sup> symporter)
- PDS (pendrin)
- TPO (thyroidal peroxidase)
- TG homodimers and their iodation MIT and DIT
- DUOX1 and 2 together with TPO oxidation of iodide and transportation to TG structure
- TPO connection DIT+DIT (T4) or DIT+MIT (T3)
- Pinocytosis and phagolysosomes
- Deiodation of MIT and DIT DEHAL1 (iodotyrosine dehalogenase)
- Other proteins (TSHR)
- Transcriptional factors (TTF-1, TTF-2, PAX8, HNF-3)



## **Dietary iodine**

| Recommended Daily Intake     |            |  |  |
|------------------------------|------------|--|--|
| Adults                       | 150 µg     |  |  |
| During pregnancy             | 200 µg     |  |  |
| Children                     | 90-120µg   |  |  |
| Typical Iodine Daily Intakes |            |  |  |
| North America (1992)         | 75-300μg   |  |  |
| Chile (1981)                 | <50-150 µg |  |  |
| Belgium (1993)               | 50-60µg    |  |  |
| Germany (1993)               | 20-70µg    |  |  |
| Switzerland (1993)           | 130-160 µg |  |  |

- Bioavailability of organic and inorganic I
- ECF + Ery, saliva, gastric juice
- breast milk
- I<sup>-</sup> filtered with passive reabsorption 60 70 %
- loss through stool (10 20  $\mu g/day)$
- Highest daily intake in Japan (several mg)
- In many countries on decrease eating habits



#### **Clinical relevance**

- Endemic goiter
- Endemic cretinism

## Iodine fate in follicular cells

#### NIS

- Concentration of I in follicular cells
- Transport of other ions (TcO<sub>4</sub><sup>-</sup>, ClO<sub>4</sub><sup>-</sup>, SCN<sup>-</sup>) clinical significance
- Salivary glands, mammary gland, choroid plexus, gastric mucosa, cytotrophoblast, syncytiotrophoblast
- Loss of ability to concentrate I in thyroid gland tumors
  TSH
  - (+) transcription
  - (+) prolonged stay in PM

#### Pendrin

- also kidneys (Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchanger) and inner ear

Chloride channel 5 (ClCn5)

- ?

#### DEHAL1

-MIT and DIT, iodine recyclation

IYD


-iodotyrosine deiodinase -MIT (+++), DIT (+)

Clinical relevance -Mutation

-Thiourea derivatives – methimazole, carbimazole, propylthiouracil (TPO)

## Oxidation, organification of iodine and MIT/DIT synthesis

- Organification = incorporation I in MIT and DIT
- TPO in cooperation with DUOX1 and DUOX2 peroxide generation
- DUOX1/2 NADPH, Ca<sup>2+</sup>-dependent oxidases
- generation of  $\rm I_2$  and  $\rm I^+$
- DUOXA2 maturation and DUOX2 incorporation
- -TSH stimulation
- T3 and T4 TPO catalysis
- Tg tyreoglobulin, 660 kDA homodimer
- Tg 134 tyrosines / 25 30 iodinated / only 3, resp. 4, participate in T4 and T3
- 3 4 molecules of T4 in Tg (physiological conditions)
- Only 1 T3 in Tg



## T3 and T4 secretion

- High supply vs low daily turnover (about 1 %)
- Supply ca 5000  $\mu g$  T4 euthyroid state for ca 50 days
- Macropinocytosis and micropinocytosis (apical membrane)
- Endocytosis
- Lysosomes fusion
- Selective proteolysis (cathepsin D and D-like thiol proteases, active at low pH)
- Release of hormones from Tg in lysosomes
- Potential cytosolic transporter? (MCT8)
- T4 available to deiodases D1 and D2 modulation of systemic conversion?
- Inhibition of T4 secretion by iodide

TSH and T3, T4 secretion

- TSHR
  - TSH binding
  - TRAb (TSHR-stimulating antibody )
  - TBAb (thyroid-blocking antibodies )

-LH (+)

- -hCG (+)
- G prot. 11 subtypes of  $\alpha$  subunit
- G<sub>s</sub>
- G<sub>q/11</sub> - PLC + Ca<sup>2+</sup>
  - iodide efflux, peroxide generation,

iodation of Tg

- PKA
  - iodide uptake
  - Tg transcription
  - transcription and generation of TPO and NIS

## T3 and T4 transport



#### TBG

- Glycoprotein
- One binding site for iodothyronine
- Half-life ca 5 days
- Clinical significance sepsis, cardiopulmonary surgery – cleavage by polymorphonuclear proteases – part of defensive reaction?

#### Transthyretin

- Binds one T4 molecule, low affinity
- Half-life ca 2 days
- CSF relevance ?
- Clinical significance amyloid polyneuropathy

#### Albumin

- Low affinity
- Little relevance for T3/T4 transport (max. 10 %)

Other – lipoproteins (3 – 6 %)

| Parameter  | Thyroxine-<br>Binding Globulin | Transthyretin          | Albumin             |  |  |
|--|--------------------------------|------------------------|---------------------|--|--|
| Molecular weight of holoprotein<br>(kDa)                         | 54,000                         | 54,000 (4<br>subunits) | 66,000              |  |  |
| Plasma concentrations ( $\mu$ mol/L)                             | 0.27                           | 4.6                    | 640                 |  |  |
| $T_4$ binding capacity as $\mu gT_4/dL$                          | 21                             | 350                    | 50,000              |  |  |
| Association constants of the major binding site (L/mol)          |                                |                        |                     |  |  |
| T <sub>4</sub>   | $1 \times 10^{10}$             | 7 × 10 <sup>7</sup>    | 7 × 10 <sup>5</sup> |  |  |
| T <sub>3</sub>   | $5 \times 10^{8}$              | $1.4 \times 10^{7}$    | $1 \times 10^5$     |  |  |
| Fraction of sites occupied by T <sub>4</sub> in euthyroid plasma | 0.31                           | 0.02                   | <0.001              |  |  |
| Distribution volume (L)  | 7                              | 5.7                    | 7.8                 |  |  |
| Turnover rate (% day)  | 13                             | 59                     | 5                   |  |  |
| Distribution of iodothyronines (% protein)                       |                                |                        |                     |  |  |
| T <sub>4</sub>   | 68                             | 11                     | 20                  |  |  |
| T <sub>3</sub>   | 80                             | 9                      | 11                  |  |  |
| T <sub>3</sub> , triiodothyronine; T <sub>4</sub> , thyroxine.   |                                |                        |                     |  |  |

Low solubility of iodothyronines determines their reversible binding and transport by plasmatic proteins.

## Free T3/T4



$$\mathbf{T}_4 + \mathbf{TBG} \stackrel{\mathbf{k}_a}{\rightarrow} \mathbf{T}_4 \ \cdot \ \mathbf{TBG}$$

Importance of glomerular filtration

Glucuronidation of T4 = elimination of T4-G through bile

| Parameter   | T <sub>3</sub> | T <sub>4</sub> |  |  |  |
|---|----------------|----------------|--|--|--|
| Production rate (nmol/day)                                | 50             | 110            |  |  |  |
| Fraction from thyroid                                     | 0.2            | 1.0            |  |  |  |
| Relative metabolic potency                                | 1.0            | 0.3            |  |  |  |
| Serum concentration                                       |                |                |  |  |  |
| Total (nmol/L)  | 1.8            | 100            |  |  |  |
| Free (pmol/L)   | 5              | 20             |  |  |  |
| Fraction of total hormone in free form $(\times 10^{-2})$ | 0.3            | 0.02           |  |  |  |
| Distribution volume (L)                                   | 40             | 10             |  |  |  |
| Fraction intracellular                                    | 0.64           | 0.15           |  |  |  |
| Half-life (days)  | 0.75           | 6.7            |  |  |  |

To convert T<sub>4</sub> from nmol/L to  $\mu$ g/dL (total) or pmol/L to ng/dL (free), divide by 12.87. To convert T<sub>3</sub> from nmol/L to ng/dL (total) or pmol/L to pg/dL (free), multiply by 65.1.

TBG concentration and saturation is the main free-T4 determinant.


## T4/T3 transport across PM and their cell fate

Expression in various tissues


T3, T4, rT3

Transport systems:

- MCT8 (monocarboxylate transporter 8)
- MCT10 (monocarboxylate transporter 10)
- OATP1C1 (organic anion transporting polypeptide 1C1) CNS (astrocytes) T4 (HEB)



## Deiodination and (seleno-)deiodinases




- all deiodinases require thiol presence as cofactor (glutathione (GSH), thioredoxin (TRX), glutaredoxin (GRX))
- D1 main source of plasmatic T3
- D3 most important "deactivating" enzyme over-expressed in tumor tissue


| Parameter  | Type 1 (Outer and<br>Inner Ring)  | Type 2 (Outer<br>Ring)  | Type 3 (Inner Ring)  |
|--|---|---|--|
| Physiologic role                                     | rT₃ and T₃S<br>degradation, the<br>source of plasma<br>T₃ in thyrotoxic<br>patients | Provide<br>intracellular T₃ in<br>specific tissues, a<br>source of plasma<br>T₃ | Inactivate $T_{3}$ and $T_{4}$   |
| Tissue location                                      | Liver, kidney,<br>thyroid, pituitary<br>(?) (not CNS)                               | CNS, pituitary,<br>BAT, placenta<br>thyroid, skeletal<br>muscle, heart          | Placenta, CNS,<br>hemangiomas, fetal<br>or adult liver,<br>skeletal muscle |
| Subcellular<br>location                              | Plasma membrane   | Endoplasmic<br>reticulum  | Plasma membrane  |
| Preferred<br>substrates<br>(position<br>deiodinated) | rT₃ (5′), T₃S (5)   | T₄, rT₃ (5′)  | T <sub>3</sub> , T <sub>4</sub> (5)  |
| K <sub>m</sub>                                       | rT₃, 10 <sup>-7</sup> ; T₄, 10 <sup>-6</sup>  | 10 <sup>-9</sup>  | 10 <sup>-9</sup>   |
| Susceptibility to<br>PTU                             | High  | Absent  | Absent   |
| Response to<br>increased T₄                          | <b>^</b>  | ¥   | <b>^</b>   |

BAT, brown adipose tissue; CNS, central nervous system;  $K_m$ , Michaelis-Menten constant; PTU, 6-n-propylthiouracil; rT<sub>3</sub>, reverse triiodothyronine; T<sub>3</sub>, triiodothy T<sub>4</sub>, thyroxine.

## Sources of intracellular T3 and T4



## T3/T4 – mechanism of action



Capillary

Local T<sub>3</sub>

Plasma T<sub>3</sub>

Nucleus


T<sub>2</sub>

**Target tissue** 


- -Heterodimer with RXR
- -TRs binding
- T3 with 15-fold affinity compared to T4

# Physiological effects of thyroid hormones

- Non-nuclear receptors
- Interactions with adaptor proteins



- cAMP
- MAPK
- Ca<sup>2+</sup>-ATPase (+)





- Regulation of transcriptional activity

- Normal growth and development
- Regulation of metabolism



## Organ-specific effects of thyroid hormones

#### Bones

- Bone growth and development
- regulation of activity of osteoblasts/clasts, chondrocytes
- hyperthyroidism risk of osteoporosis

#### Cardiovascular system

- Inotropic and chronotropic effect
- (+) cardiac output and IVF
- (-) vascular resistance
- changes in transcriptional activity:
  - -Ca<sup>2+</sup>-ATPase
  - -Phospholamban
  - -Myosin
  - $-\beta$ -AR
  - -AC
  - -Na<sup>+</sup>/Ca<sup>2+</sup> exchanger
  - -Na<sup>+</sup>/K<sup>+</sup>-ATPase

-Voltage-gated ion channels

#### GIT

- (+) monosaccharides resorption
- (+) motility

### MUNI MED

#### Adipose tissue

- (+) differentiation of adipose tissue, adipocytes proliferation
- (+) lipogenic enzymes
- (+) cell accumulation of lipids
- (+) uncoupling proteins, uncoupling of oxidative phosphorylation
- Hyperthyroidism (+) lipolysis
  - (+) β-AR
  - (-) phosphodiesterase activity
  - (+) cAMP

(+) activity HSL

- Hypothyroidism (-) lipolysis

#### Liver

- regulation of triglyceride, lipoprotein and cholesterol metabolism
- (+) fatty acids metabolism
- (+) gluconeogenesis
- (+) mitochondrial respiration

#### CNS

- expression of genes related myelination, cell differentiation, migration and signaling
- Axonal growth and further development


## TG regulation – hypothalamo-hypophyseal axis

#### TRH

- hypothalamus, CNS, C cells of TG, β cells of pancreas, myocardium, reproductive organs (prostate, testes), spinal cord
- Necessity of T3 and T4, relevance of D2
- TRH-DE (TRH-degrading ectoenzyme)

#### TSH

- Half-life ca 30 min
- Pulsatile secretion, connected to circadian rhythms
- Magnitude changes starvation, disease, surgery
- Leptin, ADH, GLP-1, glucocorticoids, α-adrenergic agonists, prostaglandins, TRH (+)
- T3/T4, gastrin, opioids, glucocorticoids (high doses), serotonin, CCK, IL-1 $\beta$  a 6, TNF- $\alpha$ , somatostatin (-)



Synthesis and secretion of thyroid hormones is regulated by feedback mechanism.

## lodide deficit and excess

#### Deficit


- Rapid T4 decrease, TSH increase
- No change in T3
- Increased synthesis of NIS, TPO, Tg, organification of iodide and Tg turnover
- Increase D2 in CNS, hypothalamus and hypophysis
- Stimulation of follicular cells (TSH)
- Long-term deficit decreased D3
- Decrease supplementation under 75 μg/day (China, India, Indonesia, Africa)
- hypothyroidismus

#### Excess

- At first increase, then decrease of iodide organification (Wolff–Chaikoff effect)
- Long-term high iodide supplementation = hypothyroidism and goitre
- decreased NIS generation
- Immediate inhibition of thyroid hormones secretion



## Functions of thyroid gland in fetus and newborn





## Thyroid gland and development stages

Fetal thyroid gland - qualitative and quantitative differences

- 10-fold higher T4 production
- D1 (-), D3 (+; liver, skin, tracheobronchial system, urothelial system, GIT epithelium) T3(-), rT3 (+)
- D2 generation of T3 in tissues
- Start at the beginning of the 3rd trimester
- TSH during whole development higher than in mother
- Almost no interaction with mother (exception placental transport of T4), high expression of D3 in uterus and placenta

Thyroid gland in newborns - qualitative and quantitative differences

- Increased TBG level
- Lower T4 levels compared to mother
- Low T3 level in serum, increased levels of rT<sub>3</sub> and T<sub>3</sub>SO<sub>4</sub>
- Rapid increase TSH 2 4 hours after birth, decrease in 48 hours
- Rapid increase T<sub>4</sub>, T<sub>3</sub>, Tg 24 hours (+D1 a D2, adrenergic stimulation of D2 in BAT)

#### Thyroid gland and aging

- Normal T4 level, decreased T3 level
- TSH according to iodide supplementation
- Benefit of decreased thyroid hormones longevity

## Thyroid gland functions during disease and starvation

#### Starvation

- Decreased plasmatic T3, increased rT3, T4 no change
- Upregulation of D3
- Decreased oxygen consumption
- Slower heart rate
- More positive nitrogen balance
- = mechanisms to save energy and proteins

#### Chronic malnutrition – decreased plasmatic T3

#### Disease

- Changes in T4 to T3 D2) conversion TSH binding
- IL-6
- Increased intra-/extracellular ROS = changes in deiodinase activity decreased T4 to T3 conversion BUT! no change in D3
- potential therapy infusion of TSH + GHRP2
- Bipolar disorder (+) TSH, (-) T4
- Severe depression (-) TSH, (+) T4

| Severity of<br>Illness | Free T <sub>3</sub>                           | Free T₄      | Reverse T <sub>3</sub> | TSH                              | Probable Cause          |
|------------------------|---|--------------|------------------------|----------------------------------|-------------------------|
| Mild                   | $\mathbf{V}$                                  | Ν            | 1                      | Ν                                | ↓ D2, D1                |
| Moderate               | $\downarrow \downarrow$                       | N, ↑↓        | ተተ                     | N, ↓                             | ↓↓ D2, D1, ? ↑<br>D3    |
| Severe                 | $\downarrow \downarrow \downarrow \downarrow$ | $\mathbf{V}$ | <b>^</b>               | $\downarrow\downarrow\downarrow$ | ↓ <b>↓</b> D2, D1, ↑ D3 |
| Recovery               | $\mathbf{v}$                                  | $\mathbf{v}$ | ۲                      | Ϋ́                               | ?                       |

D1 through D3, iodothyronine deiodinases; N, no change; T<sub>3</sub>, triiodothyronine; T<sub>4</sub>, thyroxine; TSH, thyroid-stimulating hormone (thyrotropin).

## Hormones and thyroid gland

#### Glucocorticoids

- Decreased pulsatile secretion of TSH and TRH secretion
- Increased activity (expression) of D3

#### Sex steroids

- Estrogens
  - increased TBG
  - TSH (+ 15 20 %)
- Androgen
  - decreased TBG

#### GH

- (+) T3, (-) T4
- Deiodinase

| Glucocorticoids   |   |
|---|---|
| Excess  |   |
| Decrease TSH, TBG, TTR (high-dose)                                      |   |
| Decrease serum $T_3/T_4$ and increase $rT_3/T_4$ ratios                 |   |
| Increase rT₃ production (? ↑ D3)  |   |
| Decrease T₄ and T₃ secretion in Graves disease                          |   |
| Deficiency  |   |
| Increase TSH  |   |
| Estrogen  |   |
| Increase TBG sialylation and half-life in serum                         |   |
| Increase TSH in postmenopausal women                                    |   |
| Increase T₄ requirement in hypothyroid patients                         |   |
| Androgen  |   |
| Decrease TBG  |   |
| Decrease T₄ turnover in women and reduce T₄ requirements in hypothyroid |   |
| patients  |   |
| Growth Hormone  |   |
| Decrease D3 activity  |   |
|   | - |

D3, type 3 deiodinase;  $rT_3$ , reverse  $T_3$ ;  $T_3$ , triiodothyronine;  $T_4$ , thyroxine binding globulin; TSH, thyrotropin; TTR, transthyretin.

## Hypothyroidism

Disruptions of HYP-ADH-TG axis including mutations Goitrogens and treatment

#### Primary versus secondary

- Cold sensitivity
- Dry cold skin
- Slower movements
- Slow quiet speech
- Bradycardia
- Water retention
- **Psychomotoric retardation** (children)
- Myxedema (accumulation of protein complexes, polysaccharides, hyaluronic acid and chondroitin sulfuric acid in skin)
- Hypothyroidism since birth = cretinism



## Hyperthyroidism

**Graves disease, diffusion toxic goiter,** toxic nodular goiter, inappropriate pharmacotherapy, excessive iodide intake, thyroiditidis, follicular carcinoma, tumors producing TSH

- increased BMR
- Changes in catecholamines reactivity
- Exophthalmos infiltration of lymphocytes and periocular fibroblasts into extraocular muscles and tissue
- unrest
- Tachycardia
- Hyperventilation





## Hypo-versus hyperthyroidismus

| Parameter                | Hypothyroidism  | Hyperthyroidism  |
|--------------------------|---|--|
| BMR                      | (-)   | (+)  |
| Carbohydrate metabolism  | Gluconeogenesis (-)<br>Glycogenolysis (-)<br>Glycemia (N) | Gluconeogenesis (+)<br>Glycogenolysis (+)<br>Glycemia (N)              |
| Protein metabolism       | Proteosynthesis (-)<br>Proteolysis (-)                    | Proteosynthesis (+)<br>Proteolysis (+)<br>Muscle mass (-)              |
| Lipid metabolism         | Lipogenesis (-)<br>Lipolysis (-)<br>Serum cholesterol (+) | Lipogenesis (+)<br>Lipolysis (+)<br>Serum cholesterol (-)              |
| Thermogenesis            | (-)   | (+)  |
| Autonomic nervous system | Plasmatic catecholamines (N)                              | Increased reactivity – $\beta$ -AR (+)<br>Plasmatic catecholamines (-) |

MUNI MFD

## Examination of hypothalamus – adenohypophysis – thyroid gland axis

**TSH** – immumometric methods

**Overall T3 and T4** – immunochemical methods (immunoassays)

Free T3 and T4

rT3

**Antibody levels** - (anti-Tg, anti-TPO, TSIs – thyroid-stimulating immunoglobulins

**Thyroid nodules** – ultrasound, biopsy, scan – I-123, Tc-99

MUNI Med